SCHEMBL6541404

SCHEMBL6541404

CCOC(=O)c1ccc(S(=O)(=O)c2ccc(CCCNCc3ccccc3)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.65
MAPT P10636 4/20 0.52
NAMPT P43490 1/20 0.52
POLB P06746 1/20 0.51
KMT2A Q03164 5/20 0.49
TP53 P04637 1/20 0.49
MEN1 O00255 3/20 0.48
ALDH1A1 P00352 2/20 0.48
GAA P10253 2/20 0.48
ALOX12 P18054 1/20 0.48
PKM P14618 1/20 0.47
ABL1 P00519 1/20 0.47
MAPK1 P28482 1/20 0.47
RIN1 Q13671 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CA12 O43570 3/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
CA4 P22748 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6541100 0.93 SMN1; SMN2 (0.68) SMN1; SMN2MAPTNAMPTPOLBKMT2A
SCHEMBL6540596 0.90 SMN1; SMN2 (0.82) SMN1; SMN2MAPTNAMPTPOLBKMT2A
SCHEMBL6678367 0.86 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1GAACA12
SCHEMBL6680446 0.86 KDM4E (0.48) SMN1; SMN2POLBKMT2AMEN1ALDH1A1
SCHEMBL6540593 0.85 SMN1; SMN2 (0.59) SMN1; SMN2MAPTNAMPTPOLBKMT2A
SCHEMBL6540180 0.84 SMN1; SMN2 (0.55) SMN1; SMN2MAPTPOLBKMT2ATP53
SCHEMBL6541617 0.82 CA1 (0.58) SMN1; SMN2MAPTPOLBKMT2AMEN1
SCHEMBL6680443 0.82 SMN1; SMN2 (0.54) SMN1; SMN2MAPTNAMPTKMT2AMEN1
SCHEMBL6539474 0.82 SMN1; SMN2 (0.52) SMN1; SMN2MAPTNAMPTPOLBKMT2A
SCHEMBL6541514 0.82 SMN1; SMN2 (0.53) SMN1; SMN2MAPTNAMPTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138462-A1 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2004-07-15 US disclosed
EP-1389185-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-02-18 EP disclosed
WO-2002094770-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138462-A1 Aminoalcohol derivatives BPHL, FANCD2, HRH2 SMN1; SMN2 2146/4885MAPT 4502/4885NAMPT 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.